Document is current
Any future updates will be listed below
-
Authors
Wang, Min
Yang, Jinyue
Tan, Yahong
Yuan, Shuofeng https://orcid.org/0000-0001-7996-1119
Shi, Guoli
Peng, Qi
Li, Yongqi
Poon, Vincent Kwok-Man https://orcid.org/0000-0002-7737-8912
Chan, Chris Chung-Sing https://orcid.org/0000-0001-7089-4829
Xiao, Na
Zhang, Anna Jinxia https://orcid.org/0000-0002-5087-3614
Xie, Yubin
Li, Junhua https://orcid.org/0000-0001-6466-5958
Luo, Hao
Fu, Yaning
Chen, Yong
Compton, Alex A. https://orcid.org/0000-0002-7508-4953
Zhang, Youming https://orcid.org/0009-0004-1702-6335
Yang, Yang https://orcid.org/0000-0002-6489-4459
Gao, George Fu https://orcid.org/0000-0002-3869-615X
Hou, Hongwei https://orcid.org/0000-0001-9389-4928
Chan, Jasper Fuk-Woo https://orcid.org/0000-0001-6336-6657
Yin, Yizhen https://orcid.org/0000-0003-2466-2167
- License Information
-
More Information
Article History
Received: 23 January 2025
Accepted: 7 January 2026
First Online: 26 January 2026
Competing interests
: Two patents describing potential treatments for COVID using 6L3-related peptides were applied, and the authors listed on the application are Y.S., G.F.G., M.W., J.Y., and Q.P. One patent describing potential treatments for COVID using 6L3-3P11hR and 6L3-1F3P11hR peptides was in application, and the authors listed on the application are Y.S., M.W., J.Y., Q.P., H.H., and Y.F.
